Clinical trials: Neck Anatomy
Thyroid Neoplasms
Study of Anlotinib Hydrochloride Capsules in the Treatment of Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma
The study aims to observe and investigate the efficacy and safety of Anlotinib capsules in patients with locally advanced or metastatic radioiodine-refractory differentiated thyroid carcinoma in the real world, and to summarize…
- Trial name
- NCT05994365
- Testing
- Anlotinib Hydrochloride Capsule
- Where
- 3 sites in China
- Volunteers
- 380 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Atopic Dermatitis
Ruxolitinib Cream in Participants With Facial and/or Neck Atopic Dermatitis Involvement
This is a randomized, double blind, vehicle controlled Phase 2 study with a 4-week open label extension in adolescent and adult participants with atopic dermatitis and head and/or neck involvement.
- Trial name
- NCT05127421
- Testing
- Ruxolitinib cream, Vehicle
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- Incyte Corporation
Gastric Cancer, Colon Cancer
Clinical Study of CEA Targeting Chimeric Antigen Receptor T Lymphocytes（CAR-T） for CEA Positive Advanced Malignant Solid Tumors
This study is a open-label, dose-escalating + dose-expansion clinical study, aiming to evaluate the safety and efficacy of CEA-targeted CART cell preparations, and to reliminarily observe the study drug in CEA-positive advanced…
- Conditions
- Gastric Cancer, Colon Cancer, Rectal Cancer, Breast Cancer
- Trial name
- NCT06126406
- Testing
- CEA-targeted CAR-T cells
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Head and Neck Squamous Cell Carcinoma
Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
This is a multicenter, randomized, double-blind, controlled Phase 2/3 trial of zanzalintinib in combination with pembrolizumab versus zanzalintinib-matched placebo in combination with pembrolizumab in subjects with programmed…
- Trial name
- STELLAR-305 (NCT06082167)
- Testing
- Zanzalintinib, Pembrolizumab
- Where
- 168 sites in United States, Argentina and 24 more
- Volunteers
- 600 people
- Sponsor
- Exelixis
Melanoma, Head and Neck Squamous Cell Carcinoma
A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours
The purpose of this study is to determine the appropriate dosage, safety and effectiveness of the study drug, IPN01194 in adults with advanced solid tumours. The participants in this study will have advanced solid tumours.
- Conditions
- Melanoma, Head and Neck Squamous Cell Carcinoma, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer
- Trial name
- NCT06305247
- Testing
- IPN01194
- Where
- 12 sites in United States, France and 1 more
- Volunteers
- 36 people
- Sponsor
- Ipsen
Cervical Cancer, Gastric Cancer
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of INCAGN02390 in participants with select advanced malignancies.
- Conditions
- Cervical Cancer, Gastric Cancer, Stomach Cancer, Gastroesophageal Junction Cancer
- Trial name
- NCT03652077
- Testing
- INCAGN02390
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- Incyte Corporation
Breast Cancer, Lung Cancer
Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors
The primary objective of this study is to obtain de-identified, clinically characterized, whole blood specimens to evaluate biomarkers associated with cancer for diagnostic assay development.
- Conditions
- Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer
- Trial name
- NCT03662204
- Testing
- Blood Sample Collection
- Where
- 119 sites in United States
- Volunteers
- 5,133 people
- Sponsor
- Exact Sciences Corporation
Pain, Spasm
An Effectiveness and Safety Study of Cyclobenzaprine HCl Alone or in Combination With Ibuprofen for Acute Back or Neck Muscle Pain With Muscle Spasm
The purpose of this study is to evaluate the effectiveness and safety of cyclobenzaprine HCl 5 mg (muscle spasm medication) taken three times a day, alone or in combination with ibuprofen 400 mg or 800 mg (pain relief medication)…
- Trial name
- NCT00246389
- Testing
- cyclobenzaprine hydrochloride
- Volunteers
- 1,000 people
- Sponsor
- McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC)
Pepinemab in Combination With Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
The purpose of the study is to evaluate the safety and tolerability of pepinemab in combination with pembrolizumab as first-line treatment and determine a recommended Phase 2 dose (RP2D) in patients with recurrent or metastatic…
- Trial name
- KEYNOTE-B84 (NCT04815720)
- Testing
- pepinemab + pembrolizumab
- Where
- 15 sites in United States
- Volunteers
- 49 people
- Sponsor
- Vaccinex Inc.
Head and Neck Squamous Cell Carcinoma
A Pharmacokinetic Study of Single Doses of Sativex in Treatment-induced Mucositis
To investigate what the body does to single doses of Sativex (i.e. the pharmacokinetics [PKs] of four sprays containing 10.8 mg Δ9 tetrahydrocannabinol [THC] and 10 mg cannabidiol [CBD]) when mild, moderate or severe oral…
- Trial name
- NCT01975688
- Testing
- Sativex
- Where
- United Kingdom
- Volunteers
- 10 people
- Sponsor
- GW Pharmaceuticals Ltd
Head and Neck Cancer (H&N), Oral Mucositis (Ulcerative) Due to Radiation
Oral Care Program for Mouth Side Effects During Head and Neck Radiation Therapy
People having radiation therapy to the head and neck often develop painful mouth problems - mouth sores, dry mouth, mouth pain, trouble eating and drinking, and changes in taste.
- Conditions
- Head and Neck Cancer (H&N), Oral Mucositis (Ulcerative) Due to Radiation, Stomatitis (Oral Mucositis), Xerostomia Due to Radiotherapy
- Trial name
- OSEM (NCT07885033)
- Testing
- ORAL CARE PRODUCT KIT
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- UNCANCER LLC
Squamous Non-small-cell Lung Cancer, Head and Neck Squamous Cell Carcinoma
A Study to Investigate ALE.P02 as a Monotherapy or in Combination With Pembrolizumab in Adult Patients With Selected CLDN1+ Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic, preliminary anti-tumor activity, and to determine the recommended Phase II dose (RP2D) of the ALE.P02 as a monotherapy or in…
- Conditions
- Squamous Non-small-cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Cervical Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma
- Trial name
- NCT06747585
- Testing
- ALE.P02, Pembrolizumab
- Where
- 41 sites in United States, France and 6 more
- Volunteers
- 235 people
- Sponsor
- Alentis Therapeutics AG
Squamous Cell Carcinoma of the Head and Neck (SCCHN), Metastatic Castration Resistant Prostate Cancer (mCRPC)
Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors
Evaluation of the combination of avelumab + bempegaldesleukin (NKTR-214 ) in locally advanced squamous cell carcinoma of the head and neck ( metastatic SCCHN) and avelumab + bempegaldesleukin (NKTR-214) + talazoparib or…
- Trial name
- NCT04052204
- Testing
- avelumab, Bempegaldesleukin, talazoparib
- Where
- 5 sites in United States, Belgium and 2 more
- Volunteers
- 3 people
- Sponsor
- Pfizer
Squamous Cell Carcinoma of the Head and Neck
Phase 2 Study of Imprime PGG & Pembrolizumab in Subjects With Adv SCCHN Who Failed Pembro Monotherapy or Experiencing SD
Objective: To determine the Overall Response Rate (ORR) to Imprime PGG + pembrolizumab in subjects with advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN) Safety: To characterize the safety of Imprime PGG +…
- Trial name
- NCT03246685
- Testing
- Imprime PGG, Pembrolizumab
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- HiberCell, Inc.
Head and Neck Squamous Cell Carcinoma
Study of CX1106 in Patients With Advanced Head and Neck Squamous Cell Carcinoma
CX1106 is a novel inhibitor of thymidylate synthase (TS) developed as a potential antitumor agent by virtue of the rate limiting role of TS in the biosynthesis of thymidine.
- Trial name
- HNSCC (NCT04093115)
- Testing
- CX1106
- Sponsor
- Beijing Konruns Pharmaceutical Co., Ltd.
Oral Squamous Cell Carcinoma
Verification of Saliva MMP-1 as a Diagnostic Marker of Oral Cavity Cancer
The study is designed to measure salivary matrix metalloproteinase-1 (MMP-1) using the enzyme-linked immunosorbent assay (ELISA) we developed previously in patients with oral potentially malignant disorders (OPMD), oral squamous…
- Trial name
- NCT05049408
- Testing
- MMP-1 Enzyme Linked Immunosorbent assay (ELISA)
- Where
- 2 sites in Taiwan
- Volunteers
- 1,160 people, healthy volunteers welcome
- Sponsor
- S&T Biomed Co., Ltd.
Esophageal Cancer
Discovering Patterns in Experiences of Patients in Esophageal Cancer Clinical Research
Participation in clinical trials usually favors a particular demographic group. But there is limited research available to explain what study attributes affect the completion of these specific demographic groups.
- Trial name
- NCT05831150
- Volunteers
- 500 people
- Sponsor
- Power Life Sciences Inc.
Locally Advanced or Metastatic Solid Tumors
A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors
This is an early development study of ASP388B in people with solid tumors. In this study, ASP388B will be given to people for the first time. It will be given by itself or together with standard cancer therapies.
- Trial name
- NCT07730021
- Testing
- ASP388B, Pembrolizumab, Carboplatin
- Where
- 4 sites in United States, Japan
- Volunteers
- 392 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Solid Tumor Cancer, Locally Advanced
AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
This study, the first clinical trial of AVZO-1418, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and antitumor activity of AVZO-1418 when administered intravenously as a…
- Conditions
- Solid Tumor Cancer, Locally Advanced, Metastatic Solid Tumors, Lung Cancers
- Trial name
- NCT07038343
- Testing
- AVZO-1418, Combination Agent 1, Combination Agent 2
- Where
- 27 sites in United States, China
- Volunteers
- 480 people
- Sponsor
- Avenzo Therapeutics, Inc.
Oropharyngeal Carcinoma (OPC)
A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma
The goal of this study is to understand whether CRB-701, a targeted form of chemotherapy called an anti-body drug conjugate, will work as a treatment for oropharyngeal (throat, tonsil) cancer.
- Trial name
- TEMPO-1 (NCT07768189)
- Testing
- CRB-701, capcitabine, Cetuximab (EGFR inhibitor)
- Where
- 111 sites in United States, Austria and 12 more
- Volunteers
- 260 people
- Sponsor
- Corbus Pharmaceuticals Inc.